Inventors and Patents From the City of Rahway

In the early nineteenth century, a man named Samuel Hopkins developed a three-page preprinted licensing agreement. This type of document was printed before lithography, so it probably was printed through “intaglio,” a process that involved carving text into metal plates rather than pushing ink through paper. Its appearance closely resembled that of handwritten documents. The document could have been printed in Philadelphia or Rahway, New Jersey, as both cities had printing equipment.

ISC8 has been assigned a patent for a method for electrically coupling an anti-tamper mesh to an electronic module or device

The invention is related to systems for conditioned air. It was developed by ISC8 in Costa Mesa, Calif., with four other co-inventors. The method of electrical coupling an anti-tamper mesh is described in a patent assigned to the company.

The present invention can be implemented in a variety of different forms. One embodiment involves coupling the mesh to a computer-readable storage medium. This storage medium may be a portable computer diskette, a hard disk, a random-access memory (RAM), a read-only memory (ROM), optical fiber, or any other tangible medium that stores information.

The method can further comprise a series of conductive lines arranged in any desired pattern, including a sinusoidal pattern. In another variant, conductive lines can be provided in parallel straight lines.

The patented method may comprise a tamper-respondent sensor. The anti-tamper mesh may include multiple layers of sensors that respond to physical tampering. The system may also include an input/output connector or a ribbon cable.

Another company has been awarded a patent for an anti-tamper mesh that can be integrated with a computer. The patent, issued to Applied Biosystems, is an improvement over the prior art and could make the process more convenient for users. Applied Biosystems, of Carlsbad, Calif., was assigned the patent for the method.

Another embodiment of the patented method for electrically coupling an anti-abuse device includes a multi-sensor interweaved layer 720. This layer includes a first tamper-respondent sensor 700 and a second tamper-respondent sensor 710. The second sensor further comprises an additional discrete tamper-respondent sensor 720.

Wyeth has been assigned a patent for triazine compounds as PI3 kinase and mTOR inhibitors

Triazine compounds are chemically related to other triazines, such as pyrrolidines, but their resemblance to these compounds does not mean they are identical. These compounds have different IC50 values, but they have a similar affinity for mTOR. A further benefit of these compounds is that they have the potential to inhibit both PI3 kinase and the PI3 kinase.

The patent covers triazine compounds, which are known as PI3 kinase inhibitors. These drugs have a unique structure that allows them to inhibit both PI3K and mTOR enzymes. The compounds have excellent selectivity for mTOR and PI3K, and their improved solubility gives them excellent pharmacokinetic properties.

PI3K inhibitors are important tools in treating cancer. They can help block tumor growth and promote healing by blocking PI3K activity. The compounds also inhibit Akt, a key protein in the development of apoptosis. Moreover, these compounds are known to affect the metabolism of cells by reducing cellular ATP.

However, the benefits of these drugs have not been clearly proven. This is because they are highly potent and can produce side effects, so it is important to follow the instructions carefully. Therefore, doctors and patients should be given a carefully crafted drug regimen plan.

Triazine compounds are highly potent inhibitors of mTOR and PI3 kinase. They also inhibit autophagy, a key catabolic process. This means that they are highly effective in fighting cancer. And they have the potential to treat many other diseases as well. But they’re not easy to target.

The company iBiquity Digital in Columbia, Md., has also been assigned a patent for a method and apparatus for continuous cache service in cellular networks. The patent was co-authored by Armond Capparelli and Chinmay Shah of Piscataway, N.J.

AZD8055 inhibits the activity of mTORC1. Autophagy is an important mechanism for cell survival, and inhibiting mTORC1 can protect cancer cells from death.

Amgen has been assigned a patent for benzoamide derivatives

Amgen is a biotechnology company committed to unlocking the full potential of biology. Its innovative human therapeutics harness the power of advanced human genetics to understand and solve complex human diseases. Its extensive expertise in the field enables it to develop breakthrough medicines that improve health outcomes and improve lives. The company has been a pioneer in biotechnology since 1980 and has helped millions of patients around the world. Now, it is pursuing a pipeline of medicines that will break new ground in treating disease.

Benzamide derivatives are a class of drugs that inhibit hepatic gluconeogenesis and relieve the side effects of endogenous glucocorticoids in diabetes and obesity. They also improve insulin sensitivity in muscles and adipose tissue, prevent neuronal loss, and reduce cognitive impairment.

Benzamide derivatives modulate a number of metabolic functions, including carbohydrate, protein, and lipid metabolism. They also influence normal growth, cognitive function, resistance to stress, and mineralocorticoid activity. They may also be used in combination with other therapeutic agents for treatment or prevention of disease.

One of the key features of the invention is that certain benzamide derivatives contain asymmetric centers, allowing them to exist in different enantiomeric or diastereomeric forms. These optical isomers and diastereomers can be synthesized using known techniques, including chiral chromatography. Then, optically active resolving agents can be used to separate the stereoisomers.

Hewlett-Packard Development has been assigned a patent for systems to condition air

Hewlett-Packard Development, Inc. is the sole owner of the patents assigned to HP under this Agreement. The patents have full right of assignment as set forth in Section 3.1 of the Agreement, and the patents are free of all liens, security interests, and other rights or obligations preventing them from being assigned. Furthermore, the patents have not expired, been abandoned, or have been abandoned due to a failure to pay maintenance fees.

The company has also developed instrumentation that is used in testing and developing military products. Throughout the years, the company has worked to make its products more dependent on electronic technologies. Its products have included the jet fighter and the F-15 Eagle, and Packard served as the deputy secretary of defense for President Nixon in the 1970s. During his tenure as deputy secretary of defense, he was instrumental in the development of the plans for two of the most successful jet fighter programs.

The patents assigned to HP are valuable assets that have helped the company make a billion dollars in sales. HP grants the Company research license in return for acquiring the patents. The Company acknowledges that it has other obligations related to standards-related actions.

HP relied on a simple argument to distinguish its patent from the Fitchenbaum patent. However, the prosecution history of the patent does not reflect HP’s construction of the term “conductive electrode” to include direct contact probes. Instead, the court must construe this claim in light of the relevant prior art and find that HP has not made any significant improvements to the patent.

The court has been reviewing the record, including deposition transcripts, and the revised claims. HP relies on the principle that claims may not redefine a term that is already clearly defined in the specification. HP also relies on the principle that terms in claims must be construed in light of the specification.